Neovascular Age-related Macular Degeneration Clinical Trials

286 clinical trials for Neovascular Age-related Macular Degeneration across international registries, including 40 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) — RECRUITING · PHASE3
• A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) — RECRUITING · PHASE4
• Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) — RECRUITING · PHASE3
• Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD — RECRUITING · PHASE2
• A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) — RECRUITING · PHASE3
• Extension Study for the Port Delivery System With Ranibizumab (Portal) — RECRUITING · PHASE3
• A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration — RECRUITING · PHASE3
• A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD — RECRUITING · PHASE3
• Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) — RECRUITING · PHASE3
• Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study — RECRUITING · PHASE3
• A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO — RECRUITING · PHASE2
• A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD) — RECRUITING · PHASE3
• Real-world Study of Aflibercept 8 mg in nAMD — RECRUITING
• A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD) — RECRUITING · PHASE1
• Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration — RECRUITING · PHASE3
• Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients — RECRUITING · PHASE1
• Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD — RECRUITING · PHASE4
• A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD — RECRUITING · PHASE2
• A RANDOMIZED, CONTROLLED, PARTIALLY MASKED, PHASE 3B STUDY TO ASSESS THE INJECTION BURDEN, EFFICACY, SAFETY, AND LONG-TERM PRESERVATION OF VISUAL ACUITY OF SURABGENE LOMPARVOVEC (ABBV-RGX-314) IN A REAL-WORLD CONTEXT IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION — RECRUITING · PHASE3
• Progression Suppression and Retinal Regression in VEGF-resistant AMD — RECRUITING · NA
• HIGH DOSE (HD) AFLIBERCEPT SWITCH IN NAMD: TO LOAD OR MAINTAIN? (HEIRLOOM) — RECRUITING
• Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients — RECRUITING · NA
• CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I) — RECRUITING · PHASE1
• Regulatory Post-Marketing Surveillance Study for Brolucizumab — RECRUITING
• Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) — RECRUITING · PHASE1
• A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD) — RECRUITING · PHASE1
• A PHASE IIIB/IV, MULTICENTER, RANDOMIZED, OPEN-LABEL, TWO ARM STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND DURABILITY OF FARICIMAB ADMINISTERED UP TO EVERY 24 WEEKS IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (CONSTANCE) — RECRUITING · PHASE3
• Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD) — RECRUITING · PHASE1
• Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration — RECRUITING · PHASE2
• Gene Therapy(FT-003) for Wet AMD — RECRUITING · PHASE1
• Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy — RECRUITING · PHASE2
• HOME OCT-GUIDED TREATMENT VERSUS TREAT AND EXTEND FOR THE MANAGEMENT OF NEOVASCULAR AMD — RECRUITING
• A RANDOMIZED, PARTIALLY MASKED, CONTROLLED, PHASE 3 CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RGX-314 GENE THERAPY IN PARTICIPANTS WITH NAMD — RECRUITING · PHASE3
• A PHASE 3, MULTICENTRE, DOUBLE-MASKED, RANDOMISED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVITREAL OPT-302 IN COMBINATION WITH AFLIBERCEPT, COMPARED WITH AFLIBERCEPT ALONE, IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) — RECRUITING · PHASE3
• A PHASE 3, MULTICENTRE, DOUBLE-MASKED, RANDOMISED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVITREAL OPT-302 IN COMBINATION WITH RANIBIZUMAB, COMPARED WITH RANIBIZUMAB ALONE, IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) — RECRUITING · PHASE3
• RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF HIGH DOSE AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION — RECRUITING · PHASE3
• A 64-WEEK, TWO-ARM, RANDOMIZED, DOUBLE-MASKED, MULTI-CENTER, PHASE IIIB STUDY ASSESSING THE EFFICACY AND SAFETY OF BOLUCIZUMAB 6 MG COMPARED TO AFLIBERCEPT 2 MG IN A TREAT-TO-CONTROL REGIMEN IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TALON) — RECRUITING · PHASE3
• "SAFETY AND EFFICACY OF ABICIPAR PEGOL (AGN-150998) IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. — RECRUITING
• A TWO-YEAR, RANDOMIZED, DOUBLE-MASKED, MULTICENTER, THREE-ARM STUDY COMPARING THE EFFICACY AND SAFETY OF RTH258 VERSUS AFLIBERCEPT IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION — RECRUITING
• "A 24-MONTH, PHASE IIIB, RANDOMIZED, DOUBLE-MASKED, MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF TWO TREATMENT REGIMENS OF 0.5MG RANIBIZUMAB INTRAVITREAL INJECTIONS GUIDED BY FUNCTIONAL AND/OR ANATOMICAL CRITERIA, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (OCTAVE)." — RECRUITING · PHASE3
• BEVACIZUMAB COMBINED WITH PDT, VERSUS RANIBIZUMAB AND PEGAPTANIB BOTH COMBINED WITH PDT FOR NEOVACULAR AGE RELATED MACULAR DEGENERATION CLINICAL TRIAL — ACTIVE_NOT_RECRUITING · PHASE3
• IVAN cohort extension study — COMPLETED · PHASE4
• An extension study to protocol MD7108240; pazopanib eye drops in subjects with neovascolar age-related macular degeneration — COMPLETED · PHASE2
• Treatment of neovascular age related macular degeneration with intravitreal Bevacizumab (Avastin) — COMPLETED · PHASE2
• A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib eye drops, administered for 28 days to adult subjects with choroidal neovascular age-related macular degeneration. — COMPLETED · PHASE2
• Management of recurrent or persistent choroidal neovascularization secondary to age-related macular degeneration A prospective, randomized, clinical study — COMPLETED · PHASE2
• A Phase 2b Dose-Evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration — COMPLETED · PHASE2
• Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) — ACTIVE_NOT_RECRUITING
• LEAP Strategy for Neovascular Age-Related Macular Degeneration — NOT_YET_RECRUITING · NA
• A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) — COMPLETED · PHASE3

Refine this search